ReviewNeuro-oncology advances2026
Redefining the immune microenvironment of gliomas in the era of single-cell genomics.
Review in Neuro-oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Special Issue: The Evolving Landscape of Single-Cell Genomics in CNS and PNS Oncology.Neuro-oncology advances · 2026Review
- Immune niche-associated and niche-regulated plasticity in glioblastoma: state transitions, immune escape, and therapeutic vulnerabilities.Frontiers in immunology · 2026Review
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
- Antibody-drug conjugates for primary brain tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Infiltrating gliomas are the most common primary malignant brain tumor and remain universally fatal. Over the past decade, advances in single-cell technologies, including single-cell RNA sequencing, have significantly advanced our understanding of malignant cells in glioma. These efforts have revealed extensive transcriptional heterogeneity and plasticity within glioma cells, identifying distinct cellular states and developmental programs that are discussed elsewhere. Recognizing that the tumor microenvironment constitutes sometimes more than half of the cells in gliomas, and that it has a profound impact on glioma cellular states, recent research has focused on non-malignant cells and their interactions with cancer cells. The present review reflects on lessons learned from single-cell genomics on the tumor immune microenvironment (TIME) of gliomas, as the dominant component of the tumor outside of the malignant cells and explores implications for developing effective immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.